Nexus Pharmaceuticals, Inc. v. Melinta Therapeutics, LLC
Infringement action filed 13 Dec 2024 in the United States Court of Appeals for the Federal Circuit and closed 5 Jun 2026, with 2 patents asserted. Recorded basis of termination: appeal dismissed.
Case record
- Patents involved
- US9084802B2US9278105B2
- Case no.
- 25-1282
- Verdict cause
- Infringement action
- Court
- Fed. Cir.
- Court level
- Court of Appeals
- Case region
- District of Columbia
- Chief judge
- None recorded
- Trial level
- Appeal
- Filed – Closed
- 13 Dec 2024 – 5 Jun 2026
- Duration
- 539 days
- Basis of termination
- Appeal Dismissed
- Products & marks
- Minocin® (minocycline) 100 mg/vial minocycline hydrochloride for injection · Nexus Pharmaceuticals’ 100 mg/vial generic minocycline hydrochloride for injection
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Tetracycline compositions
The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
- Legal status
- Active
- Granted
- 21 Jul 2015
- Earliest priority
- 12 Oct 2010
- Est. expiry
- 12 May 2031
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- GRIFFITH, DAVID C. · BOYER, SERGE · HECKER, SCOTT · DUDLEY, MICHAEL N.
- Classification
- A01N47/00A61K31/21A61K31/65A61K9/00A61K47/02
- Prosecution counsel
- WilmerHale
- Examiner
- RICCI, CRAIG
Tetracycline compositions
The present invention relates to compositions, pharmaceutical compositions, and methods for preparing the same, comprising a tetracycline with improved stability and solubility. Some embodiments include a tetracycline with an excess of a divalent or trivalent cation.
- Legal status
- Active
- Granted
- 8 Mar 2016
- Earliest priority
- 12 May 2010
- Est. expiry
- 12 May 2031
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- GRIFFITH, DAVID C. · BOYER, SERGE · DUDLEY, MICHAEL N. · HECKER, SCOTT
- Classification
- A01N47/00A61K47/02A61K9/00A61K31/21A61K31/65
- Prosecution counsel
- WilmerHale
- Examiner
- RICCI, CRAIG
Parties of record
Nexus Pharmaceuticals, Inc.
- Core tech
- Not recorded
- Counsel
- Helen H. Ji · Imron T. Aly · Kevin Michael Nelson · Matthew Thomas Wilkerson
- Firm
- ArentFox Schiff LLP
Melinta Therapeutics, LLC
- Core tech
- Not recorded
- Counsel
- Damien N. Dombrowski · Dominick A. Conde · Ha Kung Wong · Monica Chou
- Firm
- Venable LLP
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Helen H. Ji | Nexus Pharmaceuticals, Inc. | Plaintiff |
| Imron T. Aly | Nexus Pharmaceuticals, Inc. | Plaintiff |
| Kevin Michael Nelson | Nexus Pharmaceuticals, Inc. | Plaintiff |
| Matthew Thomas Wilkerson | Nexus Pharmaceuticals, Inc. | Plaintiff |
| Damien N. Dombrowski | Melinta Therapeutics, LLC | Defendant |
| Dominick A. Conde | Melinta Therapeutics, LLC | Defendant |
| Ha Kung Wong | Melinta Therapeutics, LLC | Defendant |
| Monica Chou | Melinta Therapeutics, LLC | Defendant |
Basis of termination
From the record · verbatim“THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED”
Case 25-1282 · Fed. Cir. · closed 5 June 2026
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 25-1282?
25-1282 is a patent infringement action brought by Nexus Pharmaceuticals, Inc. against Melinta Therapeutics, LLC, filed on 13 Dec 2024 in the United States Court of Appeals for the Federal Circuit. The case closed on 5 June 2026.
Which patents were asserted in 25-1282?
US9084802B2 (“Tetracycline compositions”), assigned to MELINTA SUBSIDIARY CORP., currently active; US9278105B2 (“Tetracycline compositions”), assigned to MELINTA SUBSIDIARY CORP., currently active. The record also lists Minocin® (minocycline) 100 mg/vial minocycline hydrochloride for injection and Nexus Pharmaceuticals’ 100 mg/vial generic minocycline hydrochloride for injection.
How was case 25-1282 terminated?
The recorded basis of termination is appeal dismissed. The termination text reads: “THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED”
How long did case 25-1282 take?
539 calendar days, from filing on 13 Dec 2024 to closure on 5 June 2026.
Who were the attorneys and the judge in 25-1282?
Helen H. Ji, Imron T. Aly, Kevin Michael Nelson and Matthew Thomas Wilkerson are recorded as counsel for plaintiff Nexus Pharmaceuticals. Damien N. Dombrowski, Dominick A. Conde, Ha Kung Wong and Monica Chou appear for defendant Melinta Therapeutics.
Disclaimer. This page reproduces publicly available court docket data for case 25-1282 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.